Editorial Ppublish
PubMed: 40008677 DOI: 10.1080/17568919.2025.2467615
Optimizing selective estrogen receptor degraders for anticancer drug development.
Future Med Chem 17(6):637-640
Authors: Neha Bhatia, Shashank Kumar, Lajya Devi Goyal, Suresh Thareja
Affiliations
- Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences Central University of Punjab, Bathinda, India.
- Molecular Signaling & Drug Discovery Laboratory, Department of Biochemistry, Central University of Punjab, Bathinda, India.
- Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, Bathinda, India.
MeSH
Drug Development, Estrogens, Breast Neoplasms, Pharmaceutical Preparations, Receptors, Estrogen, Chemistry, Pharmaceutical, Neoplasms